BrightSpec Announces $18.4 Million Financing Round Led by Genoa Ventures and Arboretum Ventures
Summary
Traditional techniques, like NMR, FT-IR, and MS, often require purified reference standards, sample preparation, and extensive method development to resolve known isomers. BrightSpec offers an extensive database of calculated and validated structural spectra and tools for the rapid identification of unknown compounds in crude samples. "We have been impressed with the market validation the BrightSpec team has achieved in early customer testing during the development of their hardware and software solutions," said Jenny Rooke, Ph.D., Founder and Managing Director of Genoa Ventures. ""Our investment in BrightSpec is based on their unique approach to solving the ubiquitous identification challenges in analytical chemistry," said Dan Kidle, Managing Partner at Arboretum Ventures. Combining the structural power of NMR with the speed, accuracy, and precision of Mass Spectrometry, MRR provides comprehensive small molecule identification in a single instrument.